Safety and Efficacy Update on First-Generation Drug-Eluting Stents

American Journal of Cardiology

Volumn 102, Issue 9 SUPPL., 2008, Pages 18J-23J

  Spaulding, Christian ^a  

^a René Descartes University ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETREATMENT; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOSIS;

EID: 54549098286     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.005     Document Type: Article

References (16)

1. Serruys P.W., Ong A.T.L., van Herwerden L.A., Sousa J., Jatene A., Bonnier J., Schönberger J., Buller N., Bonser R., and Disco C. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005) 575-581
2. Weaver W.D., Reisman M.A., Griffin J.J., Butler C., Leimgruber P., Henry T., D'Haem C., Clark V., Martin J., and Cohen D. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomized trial. Lancet 355 (2000) 2199-2203
3. Stone G.W., Ellis S.G., Colombo A., Dawkins K.D., Grube E., Cutlip D.E., Friedman M., Baim D.S., and Koglin J. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare-metal stent implantation. Circulation 115 (2007) 2842-2847
4. Schühlen H., Kastrati A., Mehilli J., Hausleiter J., Pache J., Dirschinger J., and Schömig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 147 (2004) 317-322
5. Van Belle E., Ketelers R., Bauters C., Périé M., Abolmaali K., Richard F., Lablanche J.M., McFadden E.P., and Bertrand M.E. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 103 (2001) 1218-1224
6. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
7. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M., Schömig A., Pfisterer M., Stone G., Leon M., de Lezo J., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
8. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Jüni P., Sianos G., and Hellige G. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
9. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabaté M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
10. Mauri L., Hsieh W., Massaro J.M., Ho K.K.L., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
11. Schömig A., Dibra A., Windecker S., Mehilli J., Suárez de Lezo J., Kaiser C., Park S., Goy J., Lee J., and Di Lorenzo E. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380
12. James S., Carlsson J., Lindback J., Nilsson T., Stenestrand U., Wallentin L., Lagerqvist B., and SCAAR Study Group. Long term outcomes with drug-eluting stents vs bare-metal stents in Sweden: one additional year of follow up. Slide presentation at European Society of Cardiology Congress 2007; September 2 (2007) Vienna, Austria
13. DEScover Registry: DES outperformed bare metal stents. [TCT 2006 daily press release]. http://www.tct2006.com/Dailies_TCT2006/monday_fulltext/DEScover_Registry_DES_Outperformed_Bare_Metal_Stents.html Accessed April 9, 2008
14. Applegate R.J., Sacrinty M.T., Kutcher M.A., Santos R.M., Baki T.T., Gandhi S.K., and Little W.C. Off-label DES vs BMS treatment: outcomes at 2 years. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20-25, 2007; Washington, DC. Abstract 408. http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3592 Accessed April 8, 2008
15. Maeng M., Jensen L.O., Kaltoft A., Bøttcher M., Hansen H.H.T., Krusell L.R., Thayssen P., Rasmussen K., Johnsen S.P., Pedersen L., et al. Stent thrombosis, myocardial infarction, and mortality following drug-eluting and bare metal stent coronary interventions in patients with diabetes mellitus. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20-25, 2007; Washington, DC. Abstract 66. http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3259 Accessed April 8, 2008
16. Brodie B.R., Stuckey T., Downey W., Humphrey A., Bradshaw B., Metzger C., Hermiller J., Krainin F., Juk S., Cheek H.B., et al. Outcomes and complications with off-label versus on-label use of drug-eluting stents: results from the STENT registry. Presented at the Transcatheter Cardiovascular Therapeutics 19th Annual Scientific Symposium; October 20-25, 2007; Washington, DC. Abstract 106. http://www.aievolution.com/tct0701/index.cfm?do=abs.viewAbs&abs=3299 Accessed April 8, 2008